| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/30/2006 | WO2005102275A3 Galantamine salts, method of producing it and nasal composition thereof |
| 03/30/2006 | WO2005097192A3 Active substance combination of a carbinol compound and an opioid |
| 03/30/2006 | WO2005097107A3 Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| 03/30/2006 | WO2005090372A3 Platinum carboxylate anticancer compounds |
| 03/30/2006 | WO2005071093A3 Chimpanzee adenovirus vaccine carriers |
| 03/30/2006 | WO2005067973A3 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 03/30/2006 | WO2005048946A3 Treatment for burn victims and animal carcasses |
| 03/30/2006 | WO2005048942A3 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 03/30/2006 | WO2005044246A3 Controlled release analgesic suspensions |
| 03/30/2006 | WO2005044243A3 Transdermal analgesic systems having reduced abuse potential |
| 03/30/2006 | WO2004065932A3 Methods of identifying modulators of cellular glycosylation using gtrap3-18 |
| 03/30/2006 | WO2004037196A3 Cytomodulating peptides and methods for treating neurological disorders |
| 03/30/2006 | US20060069246 Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069163 Method for treating Alzheimer's disease |
| 03/30/2006 | US20060069159 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 03/30/2006 | US20060069148 Prostaglandins for prostaglandin mediated diseases such as antihistamines |
| 03/30/2006 | US20060069126 Pharmaceutically active isoindoline derivatives |
| 03/30/2006 | US20060069113 Analgesic compositions containing buprenorphine |
| 03/30/2006 | US20060069081 beta -methyl carbapenem compounds; for multiple-drug resistant bacterial strain |
| 03/30/2006 | US20060069075 Methods for treating dry eye |
| 03/30/2006 | US20060069067 Combination of an aromatase inhibitor with a bisphosphonate |
| 03/30/2006 | US20060069065 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 03/30/2006 | US20060069031 use of agonist of hypothalamic hormone, i.e. GnRH, for preparation to support luteal phase during infertility treatment of female mammals; pharmaceutical agent supports luteal phase after spontaneous ovulation or after stimulation of follicular growth triggering final follicular maturation and ovulation |
| 03/30/2006 | US20060069014 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 03/30/2006 | US20060068439 Ucp4 |
| 03/30/2006 | US20060068438 Identification of gene expression alterations underlying the aging process in mammals |
| 03/30/2006 | US20060068389 Methods and compositions for inhibiting hiv replication |
| 03/30/2006 | US20060068015 Particulate or in solid dosage forms; a combination of fibrate and HMG CoA reductase inhibitor statins or a pharmaceutically active salts, in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration |
| 03/30/2006 | US20060067947 Immunotherapeutic for cancer |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067938 Methods for the treatment of osteoarthritis and compositions thereof |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067928 Contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [ alpha -L-iduronic acid (I) or beta -D-glucuronic acid] linked 1, 4 to alpha -D-hexosamine with a modified heparinase III in vitro |
| 03/30/2006 | US20060067885 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell |
| 03/30/2006 | CA2575265A1 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders |
| 03/29/2006 | EP1641262A1 Circuit for processing video signal containing information such as closed caption |
| 03/29/2006 | EP1640799A1 Laser projector |
| 03/29/2006 | EP1640381A2 Neurotrophic growth factor |
| 03/29/2006 | EP1640021A1 Preventive/remedy for urinary disturbance |
| 03/29/2006 | EP1640003A2 Compositions comprising a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 receptor antagonist |
| 03/29/2006 | EP1640000A2 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1638607A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| 03/29/2006 | EP1638581A2 Zwitterionic immunomodulators for the treatment of asthma and allergy |
| 03/29/2006 | EP1638567A1 Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases |
| 03/29/2006 | EP1638554A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 03/29/2006 | EP1638545A1 Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor |
| 03/29/2006 | EP1638528A2 Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy |
| 03/29/2006 | EP1638525A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 03/29/2006 | EP1638524A1 Composition and method for the treatment of water related ear disorders |
| 03/29/2006 | EP1638504A1 Non-invasive intravascular thrombolyisis using modified ultrasound techniques |
| 03/29/2006 | EP1467998B1 Tetracyclic heterocompounds as estrogen receptor modulators |
| 03/29/2006 | EP1461083B1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 03/29/2006 | EP1402270B1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 03/29/2006 | EP1385496A4 Use of compositions for treating rosacea |
| 03/29/2006 | EP1358354B1 Method for identifying compounds modulating reverse cholesterol transport |
| 03/29/2006 | EP1289552B1 Methods for treating hemostatic disorders by soluble p-selectin |
| 03/29/2006 | EP1283700B1 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/29/2006 | EP1230267B1 Membrane translocating peptide drug delivery system |
| 03/29/2006 | EP1226279B1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 03/29/2006 | EP1222266B1 Pca3 messenger rna in benign and malignant prostate tissues |
| 03/29/2006 | EP1214048B1 Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
| 03/29/2006 | EP1156789B1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 03/29/2006 | EP1146884B1 Novel polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same |
| 03/29/2006 | EP1124567B1 Buffered compositions for dialysis |
| 03/29/2006 | EP1100468B1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 03/29/2006 | EP1079847B1 Osteoporosis treatment |
| 03/29/2006 | EP1077715B1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
| 03/29/2006 | EP0990031B1 Tumor necrosis factor receptor 5 |
| 03/29/2006 | EP0793489B1 Use of statin for the treatment of skin disorders |
| 03/29/2006 | EP0751709B2 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 03/29/2006 | CN1754100A A screening method |
| 03/29/2006 | CN1753968A Antioxidative composition and composition for external use |
| 03/29/2006 | CN1753861A Novel aminobenzophenone compounds |
| 03/29/2006 | CN1753694A Remedy for spinal injury containing interleukin-6 antagonist |
| 03/29/2006 | CN1753686A Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 03/29/2006 | CN1753683A Ophthalmic formulation for the prevention and treatment of ocular conditions |
| 03/29/2006 | CN1753625A Stimulation of in vivo production of proteins with formulation comprising leucine |
| 03/29/2006 | CN1753618A Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/29/2006 | CN1752078A Aibomycin analogue, its preparation method, medicinal composition and use |
| 03/29/2006 | CN1751741A Nano carbon tube infusion agent, its prepn. method and application in treating cancer, cardiovascular disease and infectious disease |
| 03/29/2006 | CN1248514C Method and an arrangement for connecting and disconnecting communications links |
| 03/29/2006 | CN1247614C Preparation of antigen sensitized human dendron shaped cell and its use |
| 03/29/2006 | CN1247589C Tricyclic derivatives of indole with antiangiogenic activity |
| 03/29/2006 | CN1247570C Novel pyridyl cyanoguandine compounds |
| 03/29/2006 | CN1247544C Anthranilic acid amides with heteroarylsulfonyl side chain and use thereof as active substance for antiarythmia |
| 03/29/2006 | CN1247258C Combination therapy using anti-angiogenic agents and TNF alpha |
| 03/29/2006 | CA2483732A1 Toll-like receptor 3, its signalling associated molecule trif and their use thereof |
| 03/28/2006 | US7019147 E.,g.,1-[2-(5-Methoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine; anticarcinogenic and -tumor agent; KDR tyrosine kinase inhibitors; (KDR=kinase inserrt domain recepter) |
| 03/28/2006 | US7019139 Quinolinones and uses thereof |
| 03/28/2006 | US7019016 Therapy of sensorineural hearing loss in a mammal by administering NR2B subunit selective N-methyl-D-aspartate (NMDA) NR2B subtype receptor antagonist |
| 03/28/2006 | US7019013 Sulfamidothienopyrimidines |
| 03/28/2006 | US7019000 administering nitrogen-sulfur compounds, e.g. 4,4-dithiodimorpholine to inhibit binding of the E6 protein by human papilloma virus; treatment of cervical cancer |
| 03/28/2006 | US7018990 synergistic mixture with 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-[(2'-dimethylaminomethyl)imidazol-1'-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt (Razaxaban) allows for lower dosages of each agent; thromboembolic disorders; anticoagulants; decreased bleeding times |
| 03/28/2006 | US7018985 Composition and method for inhibiting platelet aggregation |
| 03/28/2006 | US7018984 Methods and compositions for controlling translation of HCV proteins |
| 03/28/2006 | US7018982 Methods useful in the treatment of bone resorption diseases |
| 03/28/2006 | US7018839 Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| 03/28/2006 | US7018797 Method for treating neurodegenerative disorders |